Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders

Christian Ammitzboell,Marianne Kragh Thomsen, Jakob Bogn Andersen,Jens Magnus Berth Jensen,Marie-Louise From Hermansen,Anders Dahl Johannsen,Mads Lamm Larsen,Clara Elbael Mistegaard,Susan Mikkelsen,Fruzsina Szabados,Signe Risbol Vils,Christian Erikstrup,Ellen-Margrethe Hauge,Anne Troldborg

Rheumatology (Oxford, England)（2022）

引用 2|浏览1

暂无评分

摘要

Continuously impaired humoral response to mRNA vaccines was found in most RTX treated patients after a booster dose or revaccination. Seroconversion was observed in approximately one-third of the patients. Measurable B-cells before boosting or revaccination was the strongest predictor of antibody response after boost or revaccination.

查看译文

关键词

B cell depleting therapy,COVID-19,autoimmune disease,mRNA vaccine,pandemic,rheumatic diseases,rituximab,vaccine,vaccine recommendation,vaccine response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要